Joana Araújo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joana Araújo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ana Catarina Pedrosa
Department of Ophthalmology, Centro Hospitalar Universitário de São João, Porto, Portugal
2 shared publications - Cláudia Oliveira-Ferreira
Department of Ophthalmology, Centro Hospitalar Universitário de São João, Porto, Portugal
2 shared publications - Joana Santos-Oliveira
Department of Ophthalmology, Centro Hospitalar Universitário de São João, Porto, Portugal
2 shared publications - Luís Figueira
Department of Ophthalmology, Unidade Local de Saúde de São João, Porto, Portugal
2 shared publications - Marta Silva
Department of Ophthalmology, Centro Hospitalar Universitário de São João, Porto, Portugal
2 shared publications - Sónia Torres-Costa
Department of Ophthalmology, Unidade Local de Saúde de São João, Porto, Portugal
2 shared publications
Latest Publications
- Open Access
- 10 February 2025
- Published by Springer Nature in Journal of Ophthalmic Inflammation and Infection
- Vol. 15 (1) , 1-6
Retinitis linked to human herpesvirus type 6: a case study in a splenectomised patient
Human herpesvirus-6 (HHV-6) is a member of the HHV family and is a rare cause of infectious uveitis. We report a case of a splenectomised patient, hospitalised due to invasive pneumococcal disease, who was diagnosed with retinitis in the right eye, with good visual acuity (0.1 LogMAR). Given the presence of HHV-6 Polymerase chain reaction (PCR) in the cerebrospinal fluid and the serum and the coexistence of a severe central nervous system infection, the ophthalmological features were attributed to the HHV-6 infection. He was treated with topical corticosteroid eyedrops, cyclopentolate, and prednisolone acetate ointment and systemically with intravenous ganciclovir 5 mg/kg bid for 14 days and then oral valganciclovir 900 mg bid for 4 weeks. The diagnosis was promptly presumed, enabling the early initiation of appropriate treatment and contributing to the preservation of the good visual acuity initially observed.
- 10 February 2025
- Published by Springer Nature in Journal of Ophthalmic Inflammation and Infection
- Vol. 15 (1) , 1-6
Open AccessRetinitis linked to human herpesvirus type 6: a case study in a splenectomised patient
Human herpesvirus-6 (HHV-6) is a member of the HHV family and is a rare cause of infectious uveitis. We report a case of a splenectomised patient, hospitalised due to invasive pneumococcal disease, who was diagnosed with retinitis in the right eye, with good visual acuity (0.1 LogMAR). Given the presence of HHV-6 Polymerase chain reaction (PCR) in the cerebrospinal fluid and the serum and the coexistence of a severe central nervous system infection, the ophthalmological features were attributed to the HHV-6 infection. He was treated with topical corticosteroid eyedrops, cyclopentolate, and prednisolone acetate ointment and systemically with intravenous ganciclovir 5 mg/kg bid for 14 days and then oral valganciclovir 900 mg bid for 4 weeks. The diagnosis was promptly presumed, enabling the early initiation of appropriate treatment and contributing to the preservation of the good visual acuity initially observed.
- Open Access
- 1 January 2025
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 16 (1) , 194-201
Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency in a Child due to Topical Ocular Corticosteroids: A Case Report
Introduction: Iatrogenic Cushing syndrome (ICS) can be caused by synthetic glucocorticoids administered through various routes. ICS caused by corticosteroid eye drops is an exceptional event, being more frequent in pediatric age. Herein, we describe a case of ICS associated with secondary adrenal insufficiency (SAI) caused by ocular topical corticosteroid treatment. Case Presentation: An 11-year-old girl was referred to our ocular inflammation department due to idiopathic, chronic, non-hypertensive, non-granulomatous bilateral anterior uveitis, treated with topical dexamethasone (eye drops, 1 mg/mL) for 1 year. During the past year, the child and her mother observed a gradual change in her physical appearance, particularly noting the development of a cushingoid facial appearance. Laboratory data revealed morning serum adrenocorticotropic hormone (ACTH) of 3.6 ng/L (7.2–63.3) and morning serum cortisol of 0.20 μg/dL (6.2–19.4). She was treated with methotrexate (15 mg/week, orally), and the topical corticosteroid regimen was progressively tapered and discontinued after 3 months. Nine months after the patient discontinued corticosteroid eye drops, her cushingoid face disappeared, and her laboratory data improved. Regarding the ophthalmological examination, the uveitis remained in remission with methotrexate, with no new episodes of intraocular inflammation. Conclusion: Although rare, ophthalmologists must be aware of ICS and SAI and prioritize using the least potent corticosteroid for the shortest duration necessary. Additionally, clinicians should avoid abrupt cessation of long-term corticosteroid therapy as this can precipitate an adrenal crisis in the presence of adrenal insufficiency.
- 1 January 2025
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 16 (1) , 194-201
Open AccessIatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency in a Child due to Topical Ocular Corticosteroids: A Case Report
Introduction: Iatrogenic Cushing syndrome (ICS) can be caused by synthetic glucocorticoids administered through various routes. ICS caused by corticosteroid eye drops is an exceptional event, being more frequent in pediatric age. Herein, we describe a case of ICS associated with secondary adrenal insufficiency (SAI) caused by ocular topical corticosteroid treatment. Case Presentation: An 11-year-old girl was referred to our ocular inflammation department due to idiopathic, chronic, non-hypertensive, non-granulomatous bilateral anterior uveitis, treated with topical dexamethasone (eye drops, 1 mg/mL) for 1 year. During the past year, the child and her mother observed a gradual change in her physical appearance, particularly noting the development of a cushingoid facial appearance. Laboratory data revealed morning serum adrenocorticotropic hormone (ACTH) of 3.6 ng/L (7.2–63.3) and morning serum cortisol of 0.20 μg/dL (6.2–19.4). She was treated with methotrexate (15 mg/week, orally), and the topical corticosteroid regimen was progressively tapered and discontinued after 3 months. Nine months after the patient discontinued corticosteroid eye drops, her cushingoid face disappeared, and her laboratory data improved. Regarding the ophthalmological examination, the uveitis remained in remission with methotrexate, with no new episodes of intraocular inflammation. Conclusion: Although rare, ophthalmologists must be aware of ICS and SAI and prioritize using the least potent corticosteroid for the shortest duration necessary. Additionally, clinicians should avoid abrupt cessation of long-term corticosteroid therapy as this can precipitate an adrenal crisis in the presence of adrenal insufficiency.